How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Area of Science:

• Obesity Medicine
• Metabolic Disorders
• Pharmacotherapy

Background:

• Obesity affects 1 in 8 globally, with lifestyle interventions (diet, exercise, behavioral modification) as primary treatment.
• Recent advancements include pharmacologic therapies, notably glucagon-like peptide 1 receptor agonists, for obesity management.
• The American Gastroenterological Association released 2022 guidelines recommending pharmacologic agents for adults with obesity unresponsive to lifestyle interventions.

Observation:

• This review examines the efficacy of lifestyle interventions for obesity treatment.
• The effectiveness of pharmacologic interventions for obesity is critically assessed.
• Expert insights guide shared decision-making for developing personalized obesity treatment plans.

Findings:

• Lifestyle interventions form the cornerstone of obesity management, showing moderate effectiveness.
• Pharmacologic interventions, including newer agents like GLP-1 RAs, demonstrate significant efficacy in weight reduction.
• Combining pharmacotherapy with lifestyle interventions yields superior outcomes compared to lifestyle interventions alone for many adults.

Implications:

• The integration of pharmacologic options into obesity treatment strategies is supported by current evidence.
• Shared decision-making is crucial for tailoring treatment plans to individual patient needs and preferences.
• These evidence-based recommendations aim to improve obesity management and patient outcomes.